Inclusion Criteria:

- All patients must be female.

- Informed consent must be signed.

- Women with locally advanced breast cancers or primary breast cancers with concomitant
gross metastatic disease are eligible. Locally advanced cancers must be of clinical
and/or radiologic size > 4 cm, and/or are deemed surgically inoperable.

- Her2/neu overexpressing tumors defined as HercepTest score of 3+, or >/= one-third of
invasive tumor showing membranous staining, or fluorescence in situ hybridization
(FISH) positive.

- Negative serum pregnancy test (bHCG) within 7 days of starting study, if of
child-bearing potential.

- Kidney and liver function tests - all within 1.5 times of the institution's upper
limit of normal.

- Performance status (World Health Organization [WHO] scale) < 2 and life expectancy >
6 months.

- Age > 18.

- No metastatic disease without concomitant primary breast cancer.

- No previous or current malignancies at other sites within the last 5 years, with
exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri
and basal or squamous cell carcinoma of the skin.

Exclusion Criteria:

- Pregnancy or unwillingness to use a reliable contraceptive method in women of
child-bearing potential.

- Severe underlying chronic illness or disease.

- Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) < 50%.

- Patients on other investigational drugs while on study.

- Severe or uncontrolled hypertension defined as blood pressure (BP) > 180/100 on three
separate occasions.

- History of congestive heart failure.

- History of coronary arterial disease.